thiamine has been researched along with Acute Confusional Senile Dementia in 41 studies
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The earliest and perhaps best example of an interaction between nutrition and dementia is related to thiamine (vitamin B1)." | 8.93 | Vitamin B1 (thiamine) and dementia. ( Cirio, RT; Elder, J; Fonzetti, P; Gibson, GE; Hirsch, JA; Jordan, BD, 2016) |
| "To determine the prevalence of plasma thiamine deficiency in patients referred to a memory disorder clinic and to compare plasma thiamine levels with red blood cell (RBC) thiamine levels." | 7.69 | Plasma and red blood cell thiamine deficiency in patients with dementia of the Alzheimer's type. ( Chen, MF; Gold, M; Johnson, K, 1995) |
| "The earliest and perhaps best example of an interaction between nutrition and dementia is related to thiamine (vitamin B1)." | 4.93 | Vitamin B1 (thiamine) and dementia. ( Cirio, RT; Elder, J; Fonzetti, P; Gibson, GE; Hirsch, JA; Jordan, BD, 2016) |
| "To determine the prevalence of plasma thiamine deficiency in patients referred to a memory disorder clinic and to compare plasma thiamine levels with red blood cell (RBC) thiamine levels." | 3.69 | Plasma and red blood cell thiamine deficiency in patients with dementia of the Alzheimer's type. ( Chen, MF; Gold, M; Johnson, K, 1995) |
| "Erythrocyte transketolase activity coefficient (ETK-AC) and affinity for coenzyme (Km TPP) were assessed in 50 patients with transketolase abnormalities such as fibromyalgia or senile dementia of Alzheimer's type, before and after magnesium (Mg), thiamin+pyridoxine (B1,B6), high energy phosphates (HEP) (phosphocreatinine of adenosine triphosphate), and piracetam." | 3.69 | Effects of magnesium, high energy phosphates, piracetam and thiamin on erythrocyte transketolase. ( Arroyo, P; Ayavou, T; Bagneres, D; Eisinger, J; Plantamura, A, 1994) |
| "The primary clinical outcome was the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)." | 2.94 | Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. ( Bettendorff, L; Chen, H; Chen, Z; Cirio, R; Flowers, SA; Fonzetti, P; Franchino-Elder, J; Gerber, LM; Gibson, GE; Grandville, T; Habeck, C; Hirsch, JA; Jordan, B; Luchsinger, JA; Schupf, N; Stern, Y; Xu, H, 2020) |
| " In order to compensate thiamine deficiency, several thiamine precursors with higher bioavailability were developed since the 1950s." | 2.72 | Neuroprotective Effects of Thiamine and Precursors with Higher Bioavailability: Focus on Benfotiamine and Dibenzoylthiamine. ( Bettendorff, L; Sambon, M; Wins, P, 2021) |
| "Because a previous short-term study demonstrated a statistically significant, but not clinically important, improvement in cognitive test scores during thiamine treatment in patients with dementia of the Alzheimer's type, a 12-month, double-blind, parallel-group study was conducted to examine whether long-term administration of thiamine at 3 g/d might slow the progression of dementia of the Alzheimer's type." | 2.67 | A trial of thiamine in Alzheimer's disease. ( Black, RS; Blass, JP; Langberg, J; Nolan, KA; Sheu, KF, 1991) |
| "Oral thiamine trials have been shown to improve the cognitive function of patients with AD; however, absorption of thiamine is poor in elderly individuals." | 2.47 | Role of thiamine in Alzheimer's disease. ( Lu'o'ng, Kv; Nguyen, LT, 2011) |
| "The neurodegeneration of Alzheimer's disease (AD) affects not only brain structures associate with cognition early in the progression of the disease, but other areas such as the hypothalamus, a region involved in the control of metabolism and appetite." | 1.72 | Benfotiamine protects against hypothalamic dysfunction in a STZ-induced model of neurodegeneration in rats. ( Cardinali, CAEF; Donato, J; Gonçalves, AC; Guerra-Shinohara, EM; Kleinridders, A; Leboucher, A; Lima, GCA; Moraes, RCM; Portari, GV; Torrão, ADS, 2022) |
| "It is well known that patients with Alzheimer's disease (AD) have imbalances in blood thiamine concentrations and lower activity of thiamine-dependent enzymes." | 1.56 | Oral benfotiamine reverts cognitive deficit and increase thiamine diphosphate levels in the brain of a rat model of neurodegeneration. ( Gonçalves, AC; Moraes, RCM; Portari, GV; Singulani, MP; Torrão, ADS, 2020) |
| "Reduced TDP levels in patients with Alzheimer's disease (AD) has been widely demonstrated and is a diagnostic biomarker for the disease." | 1.48 | High thiamine diphosphate level as a protective factor for Alzheimer's disease. ( Fei, G; Jin, L; Pan, X; Sang, S; Wang, C; Wang, L; Zhong, C, 2018) |
| " Here, we report that long-term administration of benfotiamine improved the cognitive ability of patients with AD." | 1.43 | Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer's Disease. ( Bao, W; Chen, Z; Fei, G; Guan, Y; Pan, S; Pan, X; Ren, S; Zhong, C, 2016) |
| " Here, we tested the effect of benfotiamine, a thiamine derivative with better bioavailability than thiamine, on cognitive impairment and pathology alterations in a mouse model of Alzheimer's disease, the amyloid precursor protein/presenilin-1 transgenic mouse." | 1.36 | Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. ( Chen, J; Dong, W; Fei, G; Gong, N; Gu, F; Pan, X; Qin, Y; Sun, X; Xu, TL; Xu, Z; Yu, M; Yu, Z; Zhao, J; Zhao, L; Zhong, C, 2010) |
| "Thiamine is an essential cofactor for several important enzymes involved in brain oxidative metabolism, such as the alpha-ketoglutarate dehydrogenase complex (KGDHC), pyruvate-dehydrogenase complex (PDHC), and transketolase." | 1.31 | Cerebrospinal fluid levels of thiamine in patients with Alzheimer's disease. ( de Bustos, F; Fernández-Vivancos, E; Gómez-Escalonilla, C; Hernánz, A; Jiménez-Jiménez, FJ; Medina, S; Molina, JA; Sayed, Y, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.88) | 18.7374 |
| 1990's | 11 (26.83) | 18.2507 |
| 2000's | 7 (17.07) | 29.6817 |
| 2010's | 13 (31.71) | 24.3611 |
| 2020's | 8 (19.51) | 2.80 |
| Authors | Studies |
|---|---|
| Bhawal, R | 1 |
| Fu, Q | 1 |
| Anderson, ET | 1 |
| Gibson, GE | 8 |
| Zhang, S | 1 |
| Ramamoorthy, K | 1 |
| Yoshimura, R | 1 |
| Al-Juburi, S | 1 |
| Anandam, KY | 1 |
| Kapadia, R | 1 |
| Alachkar, A | 1 |
| Abbott, GW | 1 |
| Said, HM | 1 |
| Moraes, RCM | 2 |
| Lima, GCA | 1 |
| Cardinali, CAEF | 1 |
| Gonçalves, AC | 2 |
| Portari, GV | 2 |
| Guerra-Shinohara, EM | 1 |
| Leboucher, A | 1 |
| Donato, J | 1 |
| Kleinridders, A | 1 |
| Torrão, ADS | 2 |
| Valle, ML | 1 |
| Anderson, YT | 1 |
| Grimsey, N | 1 |
| Zastre, J | 1 |
| Girgin, M | 1 |
| Isik, S | 1 |
| Kantarci-Carsibasi, N | 1 |
| Singulani, MP | 1 |
| Luchsinger, JA | 1 |
| Cirio, R | 1 |
| Chen, H | 1 |
| Franchino-Elder, J | 1 |
| Hirsch, JA | 3 |
| Bettendorff, L | 3 |
| Chen, Z | 5 |
| Flowers, SA | 1 |
| Gerber, LM | 1 |
| Grandville, T | 1 |
| Schupf, N | 1 |
| Xu, H | 1 |
| Stern, Y | 1 |
| Habeck, C | 1 |
| Jordan, B | 1 |
| Fonzetti, P | 3 |
| Sambon, M | 1 |
| Wins, P | 1 |
| Sang, S | 4 |
| Pan, X | 6 |
| Zeng, F | 1 |
| Pan, S | 3 |
| Liu, H | 3 |
| Jin, L | 4 |
| Fei, G | 6 |
| Wang, C | 3 |
| Ren, S | 2 |
| Jiao, F | 1 |
| Bao, W | 2 |
| Zhou, W | 1 |
| Guan, Y | 2 |
| Zhang, Y | 1 |
| Shi, H | 1 |
| Wang, Y | 2 |
| Yu, X | 1 |
| Zhong, C | 7 |
| Wang, L | 1 |
| Huang, HM | 1 |
| Chen, HL | 1 |
| Rommer, PS | 1 |
| Fuchs, D | 1 |
| Leblhuber, F | 1 |
| Schroth, R | 1 |
| Greilberger, M | 1 |
| Tafeit, E | 1 |
| Greilberger, J | 1 |
| Lu, J | 1 |
| Hu, W | 1 |
| Zhang, H | 1 |
| Wang, H | 2 |
| Wang, Z | 2 |
| Tan, Q | 1 |
| Qin, Y | 2 |
| Zhang, Q | 1 |
| Xie, X | 1 |
| Ji, Y | 1 |
| Cui, D | 1 |
| Gu, X | 1 |
| Xu, J | 1 |
| Yu, Y | 1 |
| Jordan, BD | 2 |
| Cirio, RT | 2 |
| Elder, J | 2 |
| Wolak, N | 1 |
| Zawrotniak, M | 1 |
| Gogol, M | 1 |
| Kozik, A | 1 |
| Rapala-Kozik, M | 1 |
| Vognar, L | 1 |
| Stoukides, J | 1 |
| Gong, N | 1 |
| Zhao, J | 1 |
| Yu, Z | 1 |
| Gu, F | 1 |
| Chen, J | 1 |
| Sun, X | 1 |
| Zhao, L | 1 |
| Yu, M | 1 |
| Xu, Z | 1 |
| Dong, W | 1 |
| Xu, TL | 1 |
| Lu'o'ng, Kv | 1 |
| Nguyen, LT | 1 |
| Molina, JA | 1 |
| Jiménez-Jiménez, FJ | 1 |
| Hernánz, A | 1 |
| Fernández-Vivancos, E | 1 |
| Medina, S | 1 |
| de Bustos, F | 1 |
| Gómez-Escalonilla, C | 1 |
| Sayed, Y | 1 |
| Balk, E | 1 |
| Chung, M | 1 |
| Raman, G | 1 |
| Tatsioni, A | 1 |
| Chew, P | 1 |
| Ip, S | 1 |
| DeVine, D | 1 |
| Lau, J | 1 |
| Blass, JP | 5 |
| Oudshoorn, C | 1 |
| Mattace-Raso, FU | 1 |
| van der Velde, N | 1 |
| Colin, EM | 1 |
| van der Cammen, TJ | 1 |
| Gold, M | 2 |
| Chen, MF | 2 |
| Johnson, K | 1 |
| Meador, KJ | 1 |
| Eisinger, J | 1 |
| Bagneres, D | 1 |
| Arroyo, P | 1 |
| Plantamura, A | 1 |
| Ayavou, T | 1 |
| Mastrogiacoma, F | 1 |
| Grisar, T | 1 |
| Kish, SJ | 1 |
| Héroux, M | 1 |
| Raghavendra Rao, VL | 1 |
| Lavoie, J | 1 |
| Richardson, JS | 1 |
| Butterworth, RF | 1 |
| Mimori, Y | 1 |
| Katsuoka, H | 1 |
| Nakamura, S | 1 |
| Kanofsky, JD | 1 |
| Hauser, RA | 1 |
| Rodríguez-Martín, JL | 2 |
| López-Arrieta, JM | 2 |
| Qizilbash, N | 2 |
| Sheu, KF | 3 |
| Cooper, AJ | 1 |
| Jung, EH | 1 |
| Agbayewa, MO | 1 |
| Bruce, VM | 1 |
| Siemens, V | 1 |
| Nolan, KA | 1 |
| Black, RS | 1 |
| Langberg, J | 1 |
| Gleason, P | 1 |
| Brush, D | 1 |
| DiPonte, P | 1 |
| Thaler, H | 1 |
| Baker, A | 1 |
| Carlson, KC | 1 |
| Harding, B | 1 |
| Perrino, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Benfotiamine in Alzheimer's Disease: A Pilot Study[NCT02292238] | Phase 2 | 71 participants (Actual) | Interventional | 2015-02-15 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Safety and Efficacy of Qualia Mind on Cognition in a Healthy Population[NCT04389723] | 60 participants (Actual) | Interventional | 2020-05-12 | Completed | |||
| Micronutrient Intervention Effects on Cognitive Outcomes in Post-Acute Traumatic Brain Injury[NCT03032302] | 30 participants (Actual) | Interventional | 2017-10-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is a brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia. It is one of the most widely used cognitive scales in clinical trials and is considered to be the gold standard for assessing antidementia treatments. The ADAS-Cog range from 0 to 70, where higher scores indicate greater cognitive dysfunction." (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | 1.39 |
| Placebo | 3.26 |
Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) is a caregiver-based Activities of Daily Living (ADL) scale composed of 23 items developed for use in dementia clinical studies. It was designed to assess the patient's performance of both basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests, as well as making judgments and decisions. The range for the total ADCS-ADL score is 0 to 78. Higher scores equate with higher functioning. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | -1.931 |
| Placebo | -3.16129 |
The AAL (Automatic Anatomical Labeling) atlas provides the taxonomy for 116 regions of interest, 90 of which capture non-cerebellar cortical regions. Signal averages from 9 cerebellar regions from each hemisphere were further averaged into one composite cerebellar region for each hemisphere, 'Cerebellum_L' and 'Cerebellum_R', which were comprised of the respective laterality averages of the regions: 'Cerebellum_Crus1 ' 'Cerebellum_Crus2 'Cerebellum_3' 'Cerebellum_4_5' 'Cerebellum_6' 'Cerebellum_7b' 'Cerebellum_8' 'Cerebellum_9' 'Cerebellum_10 '. Subsequently, these two composite regions are further combined with the bilateral paracentral lobules to provide one final composite for reference scaling. Concretely, the values from 'Cerebellum_L', 'Cerebellum_R', 'Paracentral_Lobule_L', and 'Paracentra_Lobule_R' were averaged. This final composite will serve as the denominator for the scaling operation of any ROI value prior to group-level analysis. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | ratio (Mean) |
|---|---|
| Benfotiamine | -0.02 |
| Placebo | -0.01 |
The SRT is a standard diagnostic tool in the assessment of verbal memory. The Buschke SRT immediate total scores are compared between treated (benfotiamine) and control (placebo) groups. The immediate total score is the sum of correct responses over the 6 learning trials with scores ranging from 0 to 72. A score of 0 means severe impairment in memory. A score of 72 means there is no impairment in memory. For the purpose of determining effect over several trials between groups, the fractional change from the baseline of each group is compared. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | 0.86 |
| Placebo | -1.12 |
The CDR was developed primarily for use in persons with dementia of the Alzheimer type (the equivalent of probable Alzheimer's Disease) and can also be used to stage dementia in other illnesses as well. The scores for the multiple items are summarized in one score. The CDR examines 6 categories of cognitive functioning domains. Each domain is scored on a scale ranging from 0 to 3 (including 0.5). A CDR-SB was generated as the sum of the values in each of the 6 domains. The CDR-SB sum scores range from 0 to 18, with higher scores indicating greater cognitive impairment and a 1 point worsening is considered a clinically significant symptom change. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | 0.05 |
| Placebo | 0.22 |
The NPI assesses a wide range of behaviors encountered in dementia patients to provide a means of distinguishing frequency and severity of behavioral changes. Ten behavioral and two neuro-vegetative domains are evaluated through an interview with the caregiver. The total score ranges from 0 to 144. Higher scores suggest greater psychiatric impairment. (NCT02292238)
Timeframe: Baseline, 1 year
| Intervention | score on a scale (Mean) |
|---|---|
| Benfotiamine | 6.69 |
| Placebo | 9.23 |
13 reviews available for thiamine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Neuroprotective Effects of Thiamine and Precursors with Higher Bioavailability: Focus on Benfotiamine and Dibenzoylthiamine.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents; Humans; Neuroprotection; Neuroprotective Agent | 2021 |
Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Topics: Alzheimer Disease; Biomarkers; Brain Chemistry; Diabetes Mellitus, Type 2; Glucose; Glucose Transpor | 2013 |
Vitamin B1 (thiamine) and dementia.
Topics: Alzheimer Disease; Animals; Dementia; Glucose; Humans; Randomized Controlled Trials as Topic; Thiami | 2016 |
Vitamins B1, B2, B3 and B9 - Occurrence, Biosynthesis Pathways and Functions in Human Nutrition.
Topics: Alzheimer Disease; Biological Availability; Dietary Supplements; Folic Acid; Humans; Metabolic Disea | 2017 |
Role of thiamine in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain; Humans; Pyruvate Dehydrogenase Complex; Thiamine; Thiamine Deficienc | 2011 |
Abnormal thiamine-dependent processes in Alzheimer's Disease. Lessons from diabetes.
Topics: Alzheimer Disease; Animals; Brain; Glucose; Glucose Metabolism Disorders; Humans; Thiamine | 2013 |
B vitamins and berries and age-related neurodegenerative disorders.
Topics: Aging; Alzheimer Disease; Animals; Blueberry Plants; Cognition; Disease Models, Animal; Folic Acid; | 2006 |
Thiamine-dependent processes and treatment strategies in neurodegeneration.
Topics: Alzheimer Disease; Antioxidants; Clinical Trials as Topic; Humans; Oxidative Stress; Thiamine | 2007 |
Treatment strategies for the cognitive deficits of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid; Antidepressive Agents; Cholinergic Agonists; Cognition Disorders; Humans | 1994 |
Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer's disease.
Topics: Alzheimer Disease; Humans; Phosphorylation; Thiamine | 1996 |
Thiamine for Alzheimer's disease.
Topics: Alzheimer Disease; Cognition Disorders; Humans; Thiamine | 2000 |
Thiamine for Alzheimer's disease.
Topics: Alzheimer Disease; Cognition Disorders; Humans; Thiamine | 2001 |
Thiamin and Alzheimer's disease.
Topics: Alzheimer Disease; Humans; Ketoglutarate Dehydrogenase Complex; Pyruvate Dehydrogenase Complex; Thia | 1992 |
5 trials available for thiamine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aniline Compounds; Apolipoprotein E4; Brain; Cognitive D | 2020 |
Lowered Levels of Carbonyl Proteins after Vitamin B Supplementation in Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Topics: Age Factors; Aged; Alzheimer Disease; Biomarkers; Cognitive Dysfunction; Dietary Supplements; Discri | 2016 |
Thiamine therapy in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Female; Fursultiamin; Humans; Male; Middle Ag | 1996 |
A trial of thiamine in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Double-Blind Method; Female; Humans; Male; Mental Status | 1991 |
Thiamine and Alzheimer's disease. A pilot study.
Topics: Alzheimer Disease; Behavior; Cognition; Double-Blind Method; Humans; Mental Status Schedule; Niacina | 1988 |
23 other studies available for thiamine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Serum Metabolomic and Lipidomic Profiling Reveals Novel Biomarkers of Efficacy for Benfotiamine in Alzheimer's Disease.
Topics: Alzheimer Disease; Biomarkers; Case-Control Studies; Chromatography, Liquid; Humans; Lipids; Mass Sp | 2021 |
Alzheimer's disease is associated with disruption in thiamin transport physiology: A potential role for neuroinflammation.
Topics: Acinar Cells; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cytokines; Humans; Membrane Transpo | 2022 |
Benfotiamine protects against hypothalamic dysfunction in a STZ-induced model of neurodegeneration in rats.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Rats; Streptozocin; Thiamine | 2022 |
Thiamine insufficiency induces Hypoxia Inducible Factor-1α as an upstream mediator for neurotoxicity and AD-like pathology.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Hypo | 2022 |
Proposing novel natural compounds against Alzheimer's disease targeting acetylcholinesterase.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; | 2023 |
Oral benfotiamine reverts cognitive deficit and increase thiamine diphosphate levels in the brain of a rat model of neurodegeneration.
Topics: Alzheimer Disease; Animals; Brain; Cognition; Humans; Rats; Thiamine; Thiamine Pyrophosphate | 2020 |
Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer's disease, whereas amyloid deposition does not.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein | 2018 |
High thiamine diphosphate level as a protective factor for Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Case-Control Studies; Female; Humans; | 2018 |
Interactions of endoplasmic reticulum and mitochondria Ca(2+) stores with capacitative calcium entry.
Topics: Alzheimer Disease; Animals; Calcium; Calcium Signaling; Cells, Cultured; Endoplasmic Reticulum; Fibr | 2014 |
Measurement of Blood Thiamine Metabolites for Alzheimer's Disease Diagnosis.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; Biomarkers; Female; Genotype | 2016 |
Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer's Disease.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Alzheimer Disease; Aniline Compounds; Chromatograph | 2016 |
Enhanced Activities of Blood Thiamine Diphosphatase and Monophosphatase in Alzheimer's Disease.
Topics: Acid Anhydride Hydrolases; Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoproteins E; B | 2017 |
The role of low plasma thiamin levels in cognitively impaired elderly patients presenting with acute behavioral disturbances.
Topics: Aged; Alzheimer Disease; Comorbidity; Cross-Sectional Studies; Health Surveys; Homes for the Aged; H | 2009 |
Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cerebral Cortex; Cognition; Cognition Diso | 2010 |
Cerebrospinal fluid levels of thiamine in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chromatography, High Pressure Liquid; Disease Progressio | 2002 |
Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholecalciferol; Cognition; Female; Humans; Male; Neurop | 2008 |
Plasma and red blood cell thiamine deficiency in patients with dementia of the Alzheimer's type.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Erythrocytes; Female; Humans; Male; Thiamine; Thiamine D | 1995 |
Effects of magnesium, high energy phosphates, piracetam and thiamin on erythrocyte transketolase.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Alzheimer Disease; Erythrocytes; Female; Fibromyalg | 1994 |
Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer's disease.
Topics: Acid Anhydride Hydrolases; Age Factors; Aged; Alzheimer Disease; Autopsy; Brain Chemistry; Case-Cont | 1996 |
Thiamin status and cognitive impairment in the elderly.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Humans; Thiamine; Thiamine Deficiency | 1996 |
Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Female; Humans; Male; Middle Aged; Parkinson Dise | 1998 |
Pyridoxine, ascorbic acid and thiamine in Alzheimer and comparison subjects.
Topics: Alzheimer Disease; Ascorbic Acid; Female; Humans; Male; Nutritional Status; Pyridoxine; Thiamine; Th | 1992 |
Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Brain; Erythrocytes; Female; Fibroblasts; Humans; Ketoglutarate De | 1988 |